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ABSTRACT
Background: Licorice root has been widely used to treat bronchial asthma for
many years. However, the effect of this herb on lung histopathologic features is not
fully understood.
Objective: In this study, we aimed to determine the effects of oral adminis-
tration of glycyrrhizin, an active constituent of licorice root, on lung histopathologic
features in BALB/c mice, in which the model of chronic asthma was established.
Methods: Twenty-eight BALB/c mice were divided into 4 groups: control,
lacebo, dexamethasone, and glycyrrhizin. Mice in the treatment and placebo groups
ere sensitized with 2 intraperitoneal injections of ovalbumin and then were exposed
o aerosolized ovalbumin for 30 minutes per day on 3 days each week for 8 weeks
eginning on the 21st study day. In the last week of inhalational exposure, mice in
he placebo group received saline and those in the treatment groups received either
examethasone, 1 mg/kg, or glycyrrhizin, 10 mg/kg, via orogastric gavage for 7
onsecutive days. Animals were humanely killed 24 hours after the last ovalbumin
nd drug exposure. Lung histopathologic findings were evaluated using light and
lectron microscopy.
Results: As evaluated in the control, placebo, dexamethasone, and glycyrrhizin
groups, respectively, the mean (SD) basement membrane thickness was 306.34
(36.91), 657.52 (98.99), 405.13 (96.1), and 465.01 (121.48) nm; subepithelial
smooth muscle thickness was 7.22 (1.37), 11.24 (1.85), 5.62 (1.15), and 7.76 (1.11)
m; epithelium thickness was 19.48 (1.22), 41.62 (5.49), 22.59 (3.18), and 25.54
(4.68) m; number of mast cells was 1.34 (0.19), 3.62 (0.5), 2.06 (0.77), and 2.77
0.23)/16,400 m2; and number of goblet cells was 0.32 (0.1), 4.92 (0.82), 0.66
0.06), and 0.98 (0.15)/100 m. Evaluation of lung histopathologic features dem-
onstrated that the chronic asthma model of mice was successfully established, with
significantly higher numbers of goblet and mast cells and increased thickness of
epithelium, basement membrane, and subepithelial smooth muscle layers (P 0.001
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A.B. Hocaoglu et al.for all) in the asthma group compared with in the control group. The number of
goblet (P  0.001) and mast (P  0.02) cells and the thickness of basement
membrane (P  0.001), subepithelial smooth muscle layers (P  0.001), and
epithelium of the lung (P  0.001) were found to be significantly lower in the
glycyrrhizin group compared with in the placebo group. When the glycyrrhizin and
dexamethasone groups were compared, there was no statistically significant
difference between the 2 groups in the histopathologic parameters, including
thickness of basement membrane (P  0.514), subepithelial smooth muscle (P 
0.054), and epithelium (P  1.0) and number of mast (P  0.075) and goblet
(P  0.988) cells.
Conclusions: The results of this study suggest that the group receiving
lycyrrhizin had amelioration of all established chronic histopathologic changes of
ung in the mouse model of asthma. Further studies are needed to evaluate the efficacy
f glycyrrhizin in the management of asthma. (Curr Ther Res Clin Exp. 2011;72:
50–261)
2011 Elsevier HS Journals, Inc.
Key words: airway remodeling, asthma, BALB/c mice, Glycyrrhiza glabra,
lycyrrhizin, lung histopathology.
INTRODUCTION
Asthma, the most common chronic disease in childhood, is characterized by persist-
ing airway inflammation, which leads to remodeling of the airways.1 Airway remod-
eling causes progressive structural changes in the composition, content, and organi-
zation of the cellular and molecular constituents of the airway wall.2 These structural
changes include goblet cell hyperplasia in the epithelium, mucous gland hyperplasia,
reticular basement membrane thickening, increased vascularity of mucosa, and thick-
ening of the smooth muscle layer.3
Because asthma has a chronic nature, long-term medication therapy is required for
isease management. Although corticosteroids are still accepted as the gold standard
or asthma treatment and improve asthma symptoms, they do not alter the progres-
ion of asthma or cure the disease.4 Also, concerns about adverse effects when they are
used at high doses or for a prolonged period continue to limit patient compliance.5
The chronic nature of the disease, the lack of definitive curative therapies, and the fear
of known adverse effects of current drugs encourage patients to find complementary
and alternative medicines.6 There has been huge interest in herbal medicine, and
ome studies show the potential anti-inflammatory role of these agents.7 It is known
hat 4 of the 5 classes of drugs currently used to treat asthma—2 agonists,
nticholinergics, methylxanthines, and cromones—have origins in herbal treat-
ents.8 The dramatic increase in the number of individuals with asthma has provided
new area where alternative treatment is being considered by more and more
atients, but the potential for abuse and the toxicity of herbal therapy remain
oncerns.9 Also, well-controlled clinical trials using herbal medicine for asthma
Open access under the Elsevier OA license.treatment are still rare.8,10
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Current Therapeutic ResearchGlycyrrhiza glabra, also known as licorice, is native to the Mediterranean and to
ertain areas of Asia. It is composed of triterpene saponins, flavonoids, polysaccha-
ides, pectins, simple sugars, amino acids, mineral salts, and various other sub-
tances.11 Glycyrrhizin, the major active constituent of licorice root accounting for its
sweet taste, is a triterpene glycoside that consists of 1 molecule of 18-glycyrrhetinic
cid and 2 molecules of glucuronic acid having the structure 18-glycyrrhetinic
cid-3-O--d-glucuronopyranosyl-(1¡2)--d-glucuronide.12,13 It has been reported
o have a variety of pharmacologic activities, including anti-inflammatory, antialler-
ic, and antiviral activities.14 The mechanism of action of glycyrrhizin against
nflammation could be due to the corticosteroid-like structure of 18-glycyrrhetinic
cid,15 thus mimicking the effect of cortisol by inhibiting the catalytic activity of
11-hydroxysteroid dehydrogenase.16 Although it has been reported that glycyrrhi-
in inhibits immediate airway constriction, airway hyperreactivity, lung inflamma-
ion, and infiltration of eosinophils in the airways,17 to our knowledge, there is no
study reported in the English literature evaluating the effect of this molecule on
long-term structural changes in the airway and remodeling.
In the present study, we investigated whether oral administration of glycyrrhizin,
a major constituent of the plant G glabra, would have an ameliorating effect on lung
histopathologic features, especially on airway remodeling, in a murine model of
chronic asthma.
MATERIALS AND METHODS
Experimental Animals
Six- to 8-week-old female BALB/c mice weighing 18 to 20 g were purchased
rom Bornova Veterinary Control and Research Institute (Izmir, Turkey) and were
aintained in a pathogen-free animal laboratory at Dokuz Eylul University
Izmir, Turkey). They were kept in hygienic macrolene cages in air-conditioned
ooms under a 12-hour light/12-hour dark cycle, with food and water ad libitum.
ll the animal study protocols were reviewed and approved by the Dokuz Eylul
niversity Animal Care Committee. The 28 study mice were divided into 4
roups: controls, placebo use, dexamethasone therapy, and glycyrrhizin therapy,
ach including 7 mice.
Sensitization and Inhalational Exposure
BALB/c mice were used for this study because they are high responders to
mmunoglobulin (Ig) E.18 Mice in the treatment and placebo groups were sensitized
with 2 intraperitoneal injections of 10 g/0.1 mL of chicken egg albumin (ovalbumin
[OVA], grade V, 98% pure; Sigma-Aldrich Corp., St. Louis, Missouri) with alum
as an adjuvant on days 0 and 14 of the experiment. Mice in the placebo and treatment
groups were then exposed to aerosolized OVA for 30 minutes per day on 3 days per
week for 8 weeks beginning on the 21st day of the study. Mice in the control group
received normal saline with alum intraperitoneally on days 0 and 14 of the experi-
ment and aerosolized saline without alum for 30 minutes per day on 3 days per week
for 8 weeks beginning on the 21st day of the study.18,19 Exposures were conducted
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A.B. Hocaoglu et al.in a whole-body inhalation exposure system. A solution of 2.5% OVA in normal
saline was aerosolized by delivery of compressed air to a SideStream jet nebulizer
(Philips Respironics, Pittsburgh, Pennsylvania) and was injected into a chamber. The
aerosol generated by this nebulizer comprised 80% particles with a diameter 4
m. Particle concentration was maintained in the range of 10 to 20 mg/mm3.19
Study Drugs
Glycyrrhizin was purchased from Sigma-Aldrich, and it was given at a dose of
0 mg/kg/d once daily for 7 consecutive days via orogastric gavage. Dexameth-
sone was given to the mice at a dose of 1 mg/kg/d via orogastric gavage for 7
ays. The drugs and saline were given in the last week of OVA exposure for 7
onsecutive days.
Histopathologic Analysis
Animals were humanely killed by an overdose of ketamine (500 mg/kg intraperi-
oneally) 24 hours after the last OVA and drug exposure, and histopathologic
pecimens were collected. A veterinary surgeon blinded to treatment group removed
he tissue specimens from the middle zone of the left lung of mice, and the tissue
pecimens were then coded. The remaining procedures for the evaluation of the
emoved tissue samples were performed by 2 histopathologists blinded to treatment
roup. One histopathologist evaluated the findings from light microscopy, and the
ther conducted the electron microscopic evaluation. For electron microscopic eval-
ation, tissue samples of 1 to 2 mm3 were stocked. Histopathologic samples were
xed in 10% formalin for light microscopic evaluation. After fixation, a slice from the
iddle zone of the left lung was embedded in paraffin. Serial sections cut at 5 m
were stained with hematoxylin-eosin (for routine histopathologic examination), with
toluidine blue (for enumeration of mast cells), and with periodic acid–Schiff (for
enumeration of goblet cells). Photomicrographs were taken using a JVC TK-890-E
camera (JVC, Yokohama, Japan) adapted on an Olympus BH-2 RFCA microscope
(Olympus Optical Co. Ltd., Tokyo, Japan). Serial sections were photographed at
different magnifications by skipping over 5 fields. To evaluate the thickness of
epithelium and subepithelial smooth muscle layers, measurements were taken from 4
points of each airway, and 20 measurements were taken for each mouse. Goblet cells
around the airway lumina were enumerated. Periodic acid–Schiff–positive goblet cell
numbers in 100 m of tissue sections were analyzed for each airway.
Blinded histologic analysis was performed using University of Texas Health
ciences Center San Antonio ImageTool for Windows version 3.0 software (http://
dsdx.uthscsa.edu/dig/itdesc.html) after the images were transferred from a light
icroscope to a computer.
Samples were fixed in 2% glutaraldehyde for electron microscopic evaluation. A
ibra 120 Carl Zeiss electron microscope (Carl Zeiss SMT GmbH, Oberkochen,
ermany) was used for this evaluation. Photomicrographs were taken using a JVC
K-890-E camera. Tissues were embedded in EPON after the follow-up process of
lectron microscopic evaluation. Respiratory tracts were marked from the semithin
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Current Therapeutic Researchsections. Ultrathin sections were stained with uranyl acetate and lead citrate. Basal
membrane thicknesses of samples of respiratory epithelium were examined using an
electron microscopy program (ITEM version 5.0; Olympus Soft Imaging Solutions
GmbH, Munster, Germany).
Statistical Analysis
SPSS version 11 (SPSS Inc., Chicago, Illinois) was used for statistical analysis. All
he results are presented as mean (SD) from the number of experiments indicated. The
ormally distributed results for each outcome measure were evaluated using the
olmogorov-Smirnov test. Because all the histopathologic parameters (the thickness
f epithelium, subepithelial smooth muscle layers, and basement membrane and the
umber of goblet and mast cells) were normally distributed, the differences among
roups were determined using 1-way ANOVA with Bonferroni correction. A P 
.05 was considered statistically significant.
RESULTS
The mean (SD) basement membrane thickness was 306.34 (36.91) nm (range,
242.56–382.5 nm) in the control group, 657.52 (98.99) nm (range, 500.51–778.67
nm) in the placebo group, 405.13 (96.1) nm (range, 271.98–600.14 nm) in the
dexamethasone group, and 465.01 (121.48) nm (range, 301.91–703.62 nm) in the
glycyrrhizin group. The mean (SD) epithelium thickness was 19.48 (1.22) m (range,
6.85–20.45 m) in the control group, 41.62 (5.49) m (range, 31.23–47.56 m)
n the placebo group, 22.59 (3.18) m (range, 17.51–26.54 m) in the dexameth-
sone group, and 25.54 (4.68) m (range, 19.59–35.01 m) in the glycyrrhizin
group. The mean (SD) subepithelial smooth muscle thickness was 7.22 (1.37) m
range, 4.84–9.5 m) in the control group,11.24 (1.85) m (range, 7.56–13.03 m)
n the placebo group, 5.62 (1.15) m (range, 3.32–6.69 m) in the dexamethasone
group, and 7.76 (1.11) m (range, 6.38–9.68 m) in the glycyrrhizin group.
The mean (SD) number of mast cells in the control group was 1.34 (0.19)/16,400
m2 (range, 1–1.6/16,400 m2), in the placebo group was 3.62 (0.5)/16,400 (m2)
range, 2.7–4.2/16,400 m2), in the dexamethasone group was 2.06 (0.77)/16,400
m2 (range, 0.48–2.8/16,400 m2), and in the glycyrrhizin group was 2.77 (0.23)/
16,400 m2 (range, 2.4–3.1/16,400 m2). The mean (SD) number of goblet cells
as 0.32 (0.1)/100 m (range, 0.12–0.42/100 m) in the control group, 4.92
(0.82)/100 m (range, 3.65–5.89/100 m) in the placebo group, 0.66 (0.06)/100
m (range, 0.56–0.75/100 m) in the dexamethasone group, and 0.98 (0.15)/100
m (range, 0.8–1.24/100 m) in the glycyrrhizin group. The mean (SD) and range
alues of the histopathologic parameters for all 4 groups are demonstrated in the
able.
Compared with the control group, the asthma (placebo) group had significantly
igher numbers of goblet and mast cells and increased epithelium, basement mem-
rane, and subepithelial smooth muscle layer thickness (P  0.001 for all). These
results reveal that the chronic asthma model of mice was successfully established in
this study.
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Table. Histopathologic parameters for the control, placebo (asthmatic mice), dexamethasone, and glycyrrhizin groups. Data are
given as mean (SD) [range].
Parameter Control Group Placebo Group
Dexamethasone
Group Glycyrrhizin Group
Basement membrane thickness, nm 306.34 (36.91)*
[242.56–382.5]
657.52 (98.99)
[500.51–778.67]
405.13 (96.1)*
[271.98–600.14]
465.01 (121.48)*,†
[301.91–703.62]
Subepithelial smooth muscle layer
thickness, m
7.22 (1.37)*
[4.84–9.5]
11.24 (1.85)
[7.56–13.03]
5.62 (1.15)*
[3.32–6.69]
7.76 (1.11)*,†
[6.38–9.68]
Epithelium thickness, m 19.48 (1.22)*
[16.85–20.45]
41.62 (5.49)
[31.23–47.56]
22.59 (3.18)*
[17.51–26.54]
25.54 (4.68)*,†
[19.59–35.01]
Mast cell number/16,400 m2 1.34 (0.19)*
[1–1.6]
3.62 (0.5) [2.7–4.2] 2.06 (0.77)*
[0.48–2.8]
2.77 (0.23)†,‡
[2.4–3.1]
Goblet cell number/100 m 0.32 (0.1)*
[0.12–0.42]
4.92 (0.82)
[3.65–5.89]
0.66 (0.06)*
[0.56–0.75]
0.98 (0.15)*,†
[0.8–1.24]
*P  0.001 in groups versus placebo.
†P  0.05 in the dexamethasone group versus the glycyrrhizin group.
‡P  0.02 in the glycyrrhizin group versus placebo.
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Current Therapeutic ResearchEvaluation of lung histopathologic findings demonstrate that the number of goblet
P  0.001) and mast (P  0.02) cells and the thickness of basement membrane
(P  0.001), subepithelial smooth muscle layers (P  0.001), and epithelium of the
lung (P  0.001) were significantly lower in the glycyrrhizin group compared with
the placebo group.
Comparing the glycyrrhizin and dexamethasone groups, no significant differences
were found in the number of goblet (P  0.988) and mast (P  0.075) cells or in the
thickness of basement membrane (P  0.514), subepithelial smooth muscle layers
P  0.054), and epithelium of the lung (P  1.0). The effects of placebo, dexa-
ethasone, and glycyrrhizin use on the histopathologic parameters and comparisons
mong the groups are shown in Figure 1.
Histopathologic views of airways are shown in Figures 2 and 3 In the airways of
sthmatic mice (placebo group), increased goblet cell numbers and thickened epi-
helium, basement membrane, and subepithelial smooth cell layers are seen (Figures
A and 3A). Most of the long-term histopathologic changes were ameliorated
fter dexamethasone administration (Figures 2B and 3B). Some of the long-term
hanges were alleviated after glycyrrhizin administration to asthmatic mice
Figures 2C and 3C).
DISCUSSION
Asthma is a chronic, immunologically mediated disease with a disturbance of the
normal airway repair mechanism that results in inflammatory changes and struc-
tural alterations in the airways.20 These structural changes include reticular
basement membrane thickening due to deposition of collagen, airway smooth
muscle hypertrophy/hyperplasia, goblet cell hyperplasia, and increased vascularity
of the mucosa.21–23 It seems important to prevent these structural changes
airway remodeling) in the long-term management of asthma, which prevents
rogression of disease severity.23 Although current asthma therapies are effective
n reducing inflammation, airway remodeling is poorly responsive to these med-
cations.24 Further attempts to develop new strategies to reverse airway remod-
eling are awaited.
Licorice (Glycyrrhiza) species have long been used worldwide as herbal medicines
and natural sweeteners. Licorice root is accepted as a traditional medicine used mainly
for the treatment of peptic ulcer, hepatitis C, and pulmonary and skin diseases.25 This
herb has several other useful pharmacologic properties, such as anti-inflammatory,
antiallergic, antioxidative, antimicrobial, anticancer, immunomodulatory, hepatopro-
tective, and cardioprotective effects.26 Glycyrrhizin is a triterpene glycoside obtained
from licorice root (G glabra). The antiallergic effects of licorice are mainly due to
glycyrrhizin, 18-glycyrrhetinic acid, and liquiritigenin.27 Ram et al17 demonstrated
that glycyrrhizin significantly reduces OVA-induced airway constriction and airway
hyperreactivity to methacholine and decreases lung inflammation, including eosino-
phil infiltration, in the mouse model of asthma. In this study, glycyrrhizin reduced
OVA-specific IgE levels in serum and TH2 cytokine, interleukin (IL)-4, and IL-5
levels in bronchoalveolar lavage fluid, and it prevented decreases in total IgG2a levels
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A.B. Hocaoglu et al.in serum and TH1 cytokine and interferon- levels in bronchoalveolar lavage fluid.
The results of this study indicate that glycyrrhizin modulates the TH1/TH2 paradigm
nd alleviates asthmatic features in mice.17 Glycyrrhizin has also been demonstrated
o inhibit E-selectin–, L-selectin–, and P-selectin–mediated human eosinophil and
eutrophil adhesion to umbilical vein endothelial cells.28 This component of licorice
oot also inhibits the eotaxin-1 level via STAT6 in human lung fibroblasts29 and
nuclear factor-B activity and IL-8 expression in cultured lung epithelial cells.30,31
800
700
600
500
400
300
200
100
B
as
em
en
t
M
em
br
an
e 
Th
ic
kn
es
s 
(m
m
)
Ep
ite
hl
iu
m
 T
hi
ck
ne
ss
 (m
m
)
S
ub
ep
ith
el
ia
l S
m
oo
th
M
us
cl
e 
Th
ic
kn
es
s 
(µ
m
)
N
um
be
r 
of
M
as
t 
C
el
ls
 /
 1
6
4
0
0
 µ
m
2
N
um
be
r 
of
G
ob
le
t 
C
el
ls
 (/
1
0
0
 µ
)
0
Placebo Dexamethasone
Groups
Glycyrrhizin Placebo Dexamethasone
Groups
Glycyrrhizin
Placebo Dexamethasone
Groups
GlycyrrhizinPlacebo Dexamethasone
Groups
Glycyrrhizin
Placebo Dexamethasone
Groups
Glycyrrhizin
*
*
*
*
*
*
*
*
†
*
14
12
10
8
6
4
2
0
50
45
40
35
30
25
20
15
10
5
0
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
7
6
5
4
3
2
1
0
A B
C
E
D
Figure 1. Effects of placebo, dexamethasone, and glycyrrhizin use on the thickness of (A)
basement membrane, (B) subepithelial smooth muscle, and (C) epithelium and
on the number of (D) mast cells and (E)goblet cells. Results represent the mean
(SD). *P < 0.001, compared with the placebo group. †P < 0.02 compared with
the placebo group.Although antiallergic and anti-inflammatory properties are reported, there is no study
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Current Therapeutic Researchreported in the English literature, to our knowledge, evaluating the effect of glycyr-
rhizin on airway remodeling. In the present study, we showed that mice receiving
glycyrrhizin had alleviation of all the evaluated established long-term histopathologic
changes of lung in the mouse model of asthma, including thickness of basement
membrane, epithelium, and smooth muscle layer of airways and number of goblet and
mast cells.
Dexamethasone is accepted as a potent inhibitor of airway inflammation and
remodeling.32 Administration of corticosteroids has been shown to inhibit the struc-
CA B
Figure 2. Light microscopic findings in the placebo, dexamethasone, and glycyrrhizin
groups. (A) In the placebo (asthma) group, light microscopic findings revealed
irregular respiratory epithelium. Subepithelial smooth muscle (Sm) was mark-
edly thickened. Inflammatory cell infiltration is circled (hematoxylin-eosin). (B)
In the dexamethasone group, respiratory epithelium appears regular, and the
number of goblet cells (Gc) and the thickness of the smooth muscle layer are
decreased (periodic acid–Schiff, 20). (C) In the glycyrrhizin group, airway
epithelium and parenchymal areas appear normal. The number of Gc is de-
creased (periodic acid–Schiff, 20).
A B C
Figure 3. Electron microscopic findings in the placebo, dexamethasone, and glycyrrhizin
groups. (A) In the asthma group, basement membrane (*) integrity was dis-
rupted. Cells filled with secretion granules were detected in the electron micro-
scopic evaluation. (B) In the dexamethasone group, basement membrane (*)
was regular. Secretory cells were filled with secretion granules. (C) In the
glycyrrhizin group, basement membrane (*) was regular, and cells with cilia and
secretory cells were filled with dense secretion granules and were seen as
normal.
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A.B. Hocaoglu et al.tural changes associated with airway fibrosis in other animal models.33 Although
reatment with dexamethasone, one of the most potent corticosteroids, improved all
he histopathologic parameters in the present study, no significant differences were
ound in the histopathologic parameters between the glycyrrhizin and dexamethasone
roups. Although not to a statistically significant degree, it was found that mice
iven dexamethasone had decreased smooth muscle thickness and fewer goblet
ells compared with those receiving glycyrrhizin. The similiar effectiveness of
examathasone and glycyrrhizin on long-term structural changes in asthmatic
irways in the present study may be due to the glucocorticoid-like inhibitory
ffect of glycyrrhizin in lung cells.30 Although the results of this study show that
asthmatic mice given glycyrrhizin had a benefit regarding long-term structural
changes in the airways, these data are not yet enough to claim that glycyrrhizin
could be an alternative to dexamethasone in long-term asthma treatment. More
long-term studies are needed to show the efficacy of glycyrrhizin in the treatment
of chronic asthma.
There are some important limitations of this study: cytokine levels, which have an
important role in asthma pathogenesis, could not be evaluated; a small number of
animals was used (possibility that type I and II errors exist); and the results may not
directly translate to positive findings in human clinical trials.
CONCLUSIONS
Glycyrrhizin had a beneficial effect in treating all the evaluated established long-term
histopathologic changes of lung in the mouse model of asthma. Glycyrrhizin may be
a promising alternative asthma treatment. Further studies are needed to evaluate the
effects of glycyrrhizin on asthmatic airways.
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